Neratinib
157 interactions 330 cited referencesNeratinib is used to treat a certain type of hormone receptor-positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in adults after treatment with trastuzumab (Herceptin) and other medications. Neratinib is used along with capecitabine (Xeloda) to treat a certain type of advanced horm… Read the full Neratinib drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Neratinib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Neratinib Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Neratinib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Mifepristone Korlym Increased CYP3A4 substrate with NTI exposure Details Neratinib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Neratinib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Neratinib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Neratinib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine DetailsMajor
Neratinib Abametapir Increased exposure of CYP3A4 substrate Details Neratinib Omeprazole Gastrobim Decreased neratinib solubility, absorption, and exposure Details Neratinib Relugolix Orgovyx Increased relugolix exposure Details Neratinib Colchicine Colcrys Increased exposure to P-gp substrate and risk of toxicity Details Neratinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Neratinib Cyclosporine Injection Atopica Increased neratinib exposure, an increased risk of neratinib toxicity and an increased cycloSPORINE exposure Details Neratinib Cyclosporine Ophthalmic Cequa Increased neratinib exposure, an increased risk of neratinib toxicity and an increased cycloSPORINE exposure Details Neratinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Neratinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Neratinib Dexlansoprazole Dexilant Decreased neratinib solubility, absorption, and exposure Details Neratinib Digoxin Cardoxin® Increased exposure to P-gp substrate and risk of toxicity Details Neratinib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Neratinib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Neratinib Esomeprazole Nexium Decreased neratinib solubility, absorption, and exposure Details Neratinib Esomeprazole Injection Nexium Decreased neratinib solubility, absorption, and exposure Details Neratinib Everolimus Afinitor Increased exposure to P-gp substrate and risk of toxicity Details Neratinib Famotidine Calmicid Decreased neratinib solubility, absorption, and exposure Details Neratinib Famotidine Injection Calmicid Decreased neratinib solubility, absorption, and exposure Details Neratinib Ketoconazole Topical Extina® Foam Increased neratinib exposure and risk of toxicity Details Neratinib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Neratinib Lansoprazole Prevacid Decreased neratinib solubility, absorption, and exposure Details Neratinib Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Neratinib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Neratinib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Neratinib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Neratinib Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Neratinib Nafcillin Injection Unipen® Injection Decreased exposure of neratinib and risk of reduced efficacy Details Neratinib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist